Washington University School of Medicine
Neurology
John C. Morris, MD, is the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology; Professor of Pathology and Immunology; Professor of Physical Therapy; Professor of Occupational Therapy; and Director of the Charles F. and Joanne Knight Alzheimer's Disease Research Center at Washington University School of Medicine. Dr. Morris’ research interests include healthy aging and Alzheimer dementia, antecedent biomarkers for Alzheimer disease, and trials of investigational drugs for the treatment of Alzheimer dementia. Dr. Morris has authored 4 books and more than 700 published articles (current h-index 156). Dr. Morris is a member of several professional societies and serves on numerous scientific and community advisory boards. He has received many honors and awards, including the MetLife Award for Medical Research in Alzheimer’s Disease (2004); the Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Dementias (2005); and the Carl and Gerty Cori Faculty Achievement Award, Washington University (2010). In 2013, he received the 2013 Peter H. Raven Lifetime Achievement Award from the Academy of Science of St. Louis, the Washington University School of Medicine Second Century Award, and the 2013 Medical & Scientific Honoree from the Alzheimer’s Association He is ranked in the top 1% of investigators in the field of Neuroscience and Behavior by Essential Science Indicators database.

Presenter of 1 Presentation

PRE-RECORDED: DIAGNOSTIC ACCURACY OF THE ADNI CLINICAL DIAGNOSIS OF ALZHEIMER DISEASE: A CLINICOPATHOLOGICAL STUDY

Session Type
SYMPOSIUM
Date
Sat, 19.03.2022
Session Time
05:15 PM - 07:15 PM
Room
ONSITE PLENARY: 115-117
Lecture Time
06:15 PM - 06:30 PM

Abstract

Abstract Body

Objectives: The Alzheimer Disease Neuroimaging Initiative (ADNI) aims to validate clinical diagnoses and molecular biomarkers of Alzheimer disease (AD) to inform the design of clinical trials of anti-AD investigational therapies. We examined the accuracy of these diagnoses and biomarkers for predicting the presence of neuropathological AD.

Methods: All ADNI participants who had completed neuropathological assessments through January 31, 2022, were included in the analyses. The clinical diagnosis of AD, with or without other dementing disorders, at the last ADNI assessment before death was correlated with the presence or absence of neuropathological AD, defined as “intermediate” or “high” AD Neuropathologic Change (ADNC; NIA-AA criteria). Similar correlations were examined using the last amyloid positron emission tomography (PET) results and/or amyloid-beta42, total tau, and p-tau181 measurements from the last cerebrospinal fluid (CSF) collection.

Results: In 76 ADNI participants with a clinical diagnosis of AD dementia alone (N=66) or AD dementia with other dementing disorders (N=10), intermediate or high ADNC was present in 64 (84%). AD was the sole neuropathological dementing disorder in 12 (16%) of the 76 cases. In 8 participants who were not diagnosed with AD dementia, 7 (88%) had low or absent ADNC. The predictive accuracy of amyloid PET and CSF biomarkers will be reported.

Conclusions: The ADNI clinical diagnostic accuracy of 84% for neuropathologic AD is acceptable but can be improved with the incorporation of biomarker results. Non-AD biomarkers are also needed as most neuropathologic AD cases have non-AD pathologies that could contribute to dementia and compromise anti-AD trials.

Hide